CD34 and precursor B-cell acute lymphoblastic leukemia: To this aim, we selected the CD34 positive cells from cryopreserved BM samples of four pediatric B-ALL patients with undetectable minimal residual disease (day + 78 of chemotherapy treatment) and analyzed them by FCM.